With one of the relatively newer but important anti-diabetic drugs, Vildagliptin manufactured by Novartis, losing patent protection in December, dozens of companies are readying plans to launch the generic version to get a slice of the action in the growing Rs 13,000-crore diabetes therapy. The cost of therapy is expected to reduce by over 50%.
from The Times of India https://ift.tt/2YiRItr
Subscribe to:
Post Comments (Atom)
-
With an increase in the number of individuals who want to work at their own pace in their own convenience, heading to the office for work no...
-
Liverpool finish fourth, Swansea are relegated and Tottenham win a nine-goal thriller on the final day of the Premier League season. from ...
-
One person’s recent experience at an Airbnb has the company apologizing and clarifying its rules on surveillance devices. Airbnb recently...
No comments:
Post a Comment